{'52WeekChange': -0.14077145,
 'SandP52WeekChange': 0.0644362,
 'address1': '50 Tice Boulevard',
 'address2': 'Suite 315',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 49.89,
 'askSize': 1100,
 'averageDailyVolume10Day': 101337,
 'averageVolume': 163753,
 'averageVolume10days': 101337,
 'beta': 1.00168,
 'beta3Year': None,
 'bid': 46.5,
 'bidSize': 900,
 'bookValue': 13.307,
 'category': None,
 'circulatingSupply': None,
 'city': 'Woodcliff Lake',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 49.175,
 'dayLow': 47.29,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 34.955,
 'enterpriseToRevenue': 3.133,
 'enterpriseValue': 601855552,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 47.974857,
 'fiftyTwoWeekHigh': 64.94,
 'fiftyTwoWeekLow': 33.8,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 10984771,
 'forwardEps': 3,
 'forwardPE': 15.889999,
 'fromCurrency': None,
 'fullTimeEmployees': 108,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.12666,
 'heldPercentInstitutions': 0.94138,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/eagleus.com',
 'longBusinessSummary': 'Eagle Pharmaceuticals, Inc., a specialty '
                        'pharmaceutical company, focuses on developing and '
                        'commercializing injectable products primarily in the '
                        'critical care and oncology areas in the United '
                        'States. The company offers Argatroban, an '
                        'anti-coagulant thrombin inhibitor for heparin-induced '
                        'thrombocytopenia; Ryanodex for malignant '
                        'hyperthermia; and Belrapzo and Bendeka for chronic '
                        'lymphocytic leukemia and indolent B-cell '
                        "non-Hodgkin's lymphoma. Its product candidates also "
                        'includes EP-4104, a dantrolene sodium for exertional '
                        'heat stroke, as well as to treat organophosphate '
                        'exposure; EP-5101 (PEMFEXY) for lung cancer and '
                        'mesothelioma; EGL-5385-C-1701 (fulvestrant) for '
                        'breast cancer; and Vasopressin injection, which is '
                        'indicated to enhance blood pressure in adults with '
                        'vasodilatory shock. The company has a strategic '
                        'collaboration with Tyme Technologies, Inc. to advance '
                        'oral SM-88 for the treatment of patients with cancer. '
                        'Eagle Pharmaceuticals, Inc. was founded in 2007 and '
                        'is headquartered in Woodcliff Lake, New Jersey.',
 'longName': 'Eagle Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 652368704,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_3474216',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 2469000,
 'nextFiscalYearEnd': 1640908800,
 'open': 48.88,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 20.86,
 'phone': '201 326 5300',
 'previousClose': 48.88,
 'priceHint': 2,
 'priceToBook': 3.582325,
 'priceToSalesTrailing12Months': 3.3955076,
 'profitMargins': 0.01285,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 49.175,
 'regularMarketDayLow': 47.29,
 'regularMarketOpen': 48.88,
 'regularMarketPreviousClose': 48.88,
 'regularMarketPrice': 48.88,
 'regularMarketVolume': 126793,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 13685100,
 'sharesPercentSharesOut': 0.1461,
 'sharesShort': 1999018,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1817550,
 'shortName': 'Eagle Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.2315,
 'shortRatio': 10.59,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'EGRX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 0.177,
 'trailingPE': 269.32202,
 'twoHundredDayAverage': 49.69914,
 'volume': 126793,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.eagleus.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '07677'}